Cytek Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTKB research report →
Range $5 – $6
Price Chart
About the company
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers.
- CEO
- Wenbin Jiang
- IPO
- 2021
- Employees
- 700
- HQ
- Fremont, CA, US
Get TickerSpark's AI analysis on CTKB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $800.40M
- P/E
- -10.03
- PEG
- 0.03
- P/S
- 3.98
- P/B
- 2.56
- EV/EBITDA
- -26.51
- Div Yield
- 0.00%
- Gross Margin
- 54.75%
- Op Margin
- -21.13%
- Net Margin
- -39.10%
- ROE
- -24.74%
- ROIC
- -11.76%
Latest fiscal year · YoY change
- Revenue
- $201.49M+0.5%
- Gross Profit
- $104.46M-6.0%
- Op Income
- $-40,384,000
- Net Income
- $-66,539,000-1005.3%
- EPS
- $-0.52-1030.4%
- OCF Growth
- -118.5%
- FCF Growth
- -140.1%
- 52W High
- $6.39
- 52W Low
- $3.31
- 50D MA
- $5.60
- 200D MA
- $4.69
- Beta
- 1.14
- RSI (14)
- 62
- Avg Volume
- 1.30M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cytek posted a solid Q3 with modest revenue growth, significantly higher gross margin, and reaffirmed its full-year revenue outlook while signaling a stronger Q4.· November 4, 2026
- Q3 revenue was $53.2 million, up 2% year over year, with U.S. revenue up 12% and service revenue up 13%.
- Gross margin improved sharply to 59% from 53% last year, helped by lower manufacturing costs, lower tariffs, and better service margins.
- High-end products remained the growth engine: Aurora, Aurora EVO and Borealis revenue grew over 30%, and EVO placements nearly doubled year over year.
- Management narrowed full-year 2026 revenue guidance to $208 million-$211 million and kept adjusted EBITDA expected to be around breakeven.
- The company said legal expenses should fall in Q4 after the patent trial, and it postponed the new business-unit structure rollout to 2027.
Cytek reported Q3 2026 revenue of $53.2 million, up 2% year over year. GAAP gross profit was $31.2 million, implying a 59% gross margin versus 53% in Q3 2025. GAAP net loss was $6.1 million versus a $5.5 million loss a year ago, and loss from operations improved to $8.4 million from $9.2 million. Adjusted EBITDA was $0.7 million versus $2.5 million in Q3 2025. By segment, U.S. revenue was $30.4 million, EMEA was $12.5 million, APAC was $8.3 million, academic and government revenue was $24.5 million, and biopharma/distributor/CRO revenue was $28.7 million. Cash, cash equivalents, restricted cash and marketable securities totaled $256 million at quarter-end. For Q4, management expects revenue to be meaningfully higher than Q3 due to seasonality and service growth. For full-year 2026, revenue guidance was narrowed to $208 million-$211 million, midpoint unchanged, and adjusted EBITDA is expected to be around breakeven.
Wenbin Jiang framed the quarter as evidence that Cytek’s technology leadership is intact, especially at the high end. He highlighted strong demand for Aurora EVO, growing interest in Borealis, and the launch of Cytek Cloud analysis as part of a broader digital ecosystem strategy. His tone was constructive and confident, emphasizing share gains, improving profitability, and better performance ahead in 2027 as new products and clinical initiatives scale.
Bill McCombe emphasized that higher gross margin was the quarter’s standout financial result, with GAAP gross margin rising to 59% from 53% last year and product gross margin increasing to 61% from 53%. He said the margin improvement reflected the completion of manufacturing transfer from Seattle to Singapore, lower material costs, and lower tariffs, while service gross margin rose to 53% from 51%. He also noted operating expenses rose to $39.6 million, with G&A up due to a $3 million increase in patent-litigation legal costs, and said those legal expenses should decline by $3 million to $4 million in Q4. Cash was $256 million at quarter-end, and he guided to stronger Q4 revenue and adjusted EBITDA improving meaningfully as seasonality lifts sales and litigation spending falls.
Analysts asked whether the 2026 guidance implies service revenue should keep growing at a low double-digit pace and whether product revenue will fill in the rest; management said service revenue has been growing fairly consistently and should continue at similar recent rates. Questions also focused on whether 2027 growth should be judged off the second half of 2026; management declined to give formal 2027 guidance but said it expects to outgrow the market and peers, with Borealis full imaging planned for 2027 and continued investment in high-end, low/mid-range, and reagent offerings. On biopharma demand, management said the category is up 3% year to date, has been lumpy, and APAC weakness has weighed on reported growth, but they remain positive, especially in the U.S. On supply constraints, management said it generally ships what it books within the quarter, other than small amounts, and that Borealis and enhanced-Aurora EVO production is being ramped.
The bull case is that Cytek is gaining traction with premium products, especially Aurora EVO, while Borealis is starting to attract early interest and Cytek Cloud is expanding its user base to nearly 30,000. Gross margin improved dramatically, suggesting manufacturing changes and mix are working, and management expects further operating leverage as revenue rises seasonally in Q4. Management also sounded confident about outgrowing the market in 2027 and improving profitability.
The bear case is that growth is still modest overall at 2% year over year, while APAC was down 25% and biopharma/distributor/CRO revenue fell about 17% amid lumpiness and macro pressure. Operating expenses remain elevated, with patent litigation adding about $3 million to G&A in Q3, and profitability is still near breakeven despite the margin improvement. Management also postponed the new business-unit structure to 2027, suggesting internal execution risk remains a consideration.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 80.9%
- Shares Outstanding
- 130.78M
- Float Shares
- 105.80M
of shares held by institutions
156 13F filers
Buy/sell ratio 0.64. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 12.19M | ▲ 2.61M |
| Vanguard Group Inc | 7.48M | ▲ 541.97K |
| Millennium Management LLC | 7.28M | ▼ 2.06M |
| Hhlr Advisors, Ltd. | 6.66M | 0 |
| Boston Partners | 6.53M | ▼ 1.13M |
| Topline Capital Management, LLC | 6.52M | ▲ 240.58K |
| Vanguard Capital Management LLC | 4.89M | ▼ 52.51K |
| Geode Capital Management, LLC | 3.07M | ▲ 7.28K |
| Acadian Asset Management LLC | 2.72M | ▲ 1.34M |
| Dimensional Fund Advisors LP | 2.57M | ▼ 48.82K |
| State Street Corp | 2.55M | ▼ 13.49K |
| Russell Investments Group, Ltd. | 2.43M | ▲ 917.43K |
Held by 175 ETFs
Biggest fund positions in CTKB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | Feuchtwang Ilan | other | 25,745 |
| Aug 18, 26 | Jiang Wenbin | other | 57,212 |
| Aug 18, 26 | Jiang Wenbin | other | 20,956 |
| Aug 18, 26 | Jiang Wenbin | other | 29,002 |
| Aug 18, 26 | Jiang Wenbin | other | 7,062 |
| Aug 18, 26 | Jiang Wenbin | other | 22,100 |
| Aug 18, 26 | Jiang Wenbin | other | 5,382 |
| Aug 18, 26 | Jiang Wenbin | other | 11,781 |
| Aug 18, 26 | Jiang Wenbin | other | 2,869 |
| Aug 18, 26 | Jiang Wenbin | other | 57,212 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CTKB coverage
Recent articles, reports, and earnings notes.
No research on CTKB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTKB report →Cytek Biosciences to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 18
Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year
globenewswire.com · Nov 5
Cytek Biosciences, Inc. (CTKB) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 4
Cytek Biosciences Q3 Earnings Call Highlights
marketbeat.com · Nov 4
Cytek Biosciences Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 4
Cytek Biosciences to Participate in Upcoming Investor Conferences
globenewswire.com · Oct 29
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
zacks.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.